- Home
- BNTC
as 12-18-2024 12:32pm EST
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 88.1M | IPO Year: | N/A |
| Target Price: | $23.83 | AVG Volume (30 days): | 52.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.69 - $13.29 | Next Earning Date: | 02-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Benitec Biopharma Inc. (BNTC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director10% Owner | Dec 3 '24 | Buy | $9.60 | 42,000 | $403,200.00 | 7,957,365 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director10% Owner | Nov 19 '24 | Buy | $9.98 | 41,436 | $416,615.92 | 7,957,365 |
Latest Benitec Biopharma Inc. News
BNTC Breaking Stock News: Dive into BNTC Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Benitec Biopharma initiated with a Buy at H.C. Wainwright
MT Newswires
2 days ago
HC Wainwright Initiates Benitec Biopharma at Buy With $28 Price Target
MT Newswires
5 days ago
Baird Initiates Benitec Biopharma at Outperform With $30 Price Target
Zacks
9 days ago
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
Zacks
9 days ago
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
GlobeNewswire
22 days ago
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
GlobeNewswire
a month ago
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
GlobeNewswire
a month ago
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Compare BNTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BNTC Benitec Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.